PACAP-1 will evaluate to what extent an enhanced implementation of best practices in pancreatic cancer care leads to a prolonged survival and improvement of quality of life as compared to current practice.
Rationale: The Dutch Pancreatic Cancer Project (PACAP) is an initiative of the Dutch Pancreatic Cancer Group and was officially launched in July 2014. PACAP is 1 of the largest nationwide collaborative outcomes registration and biobanking projects on pancreatic and periampullary cancer worldwide and includes the Dutch Pancreatic Cancer Audit (DPCA), the Patient Reported Outcome Measures (PROMs), an online expert panel, and the Netherlands Cancer Registry (NCR, Netherlands Comprehensive Cancer Organization; IKNL). During the first 3 years of PACAP, regional variations in treatment and guideline (non-)compliance were observed. These differences may lead to differences in survival and quality of life of pancreatic cancer patients throughout the Netherlands. From PACAP data and literature, best practices for pancreatic cancer care have been identified. Objective: The aim of PACAP-1 is to evaluate to what extent an enhanced implementation of best practices in pancreatic cancer care in the Netherlands leads to a prolonged survival and improvement of quality of life as compared to current practice. Study design: The PACAP-1 trial is a nationwide stepped-wedge cluster randomized controlled trial. In a per center stepwise and randomized manner, best practices in pancreatic cancer care are implemented in all 17 Dutch pancreatic centers. A regional pancreatic cancer team will be established per pancreatic center that functions as point of contact for peripheral centers in the region. Patient outcomes and compliance will be monitored by the registries founded in the PACAP initiative. Study Population: Prospective cohort of all pancreatic cancer patients diagnosed and treated in the Netherlands. Interventions: Best practices will be implemented in 3 key medical specialties in pancreatic cancer care: medical oncology, surgery and gastroenterology. Best practices will be implemented in centers during a 6 week intensive initiation period which includes monitoring, return visits, provider feedback in combination with education and reminders. The best practices follow the Dutch guideline on pancreatic cancer and the current state of the literature and can be executed without additional overall costs per center. Main study outcomes: The primary outcome is 1-year overall survival. Secondary outcomes include quality of life (first secondary outcome), 3- and 5-year overall survival and success of implementation of every PACAP-1 intervention and participation in DPCG randomized trials.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
4,000
All best practices follow the current state of the Dutch guideline on pancreatic cancer and the literature.
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
Academic Medical Center
Amsterdam, Netherlands
Onze Lieve Vrouwen Gasthuis
Amsterdam, Netherlands
1-year overall survival
Overall survival 1-year after diagnosis of pancreatic cancer
Time frame: 1-year
3-year overall survival
Overall survival 3-year after diagnosis of pancreatic cancer
Time frame: 3-year
5-year overall survival
Overall survival 5-year after diagnosis of pancreatic cancer
Time frame: 5-year
Complications
Complications of chemotherapy (toxicity grade 3-4 and type of toxicity) and biliary stent placement
Time frame: Through study completion, on average up to 25 months
Effect of implementation of best practices
Proportion of patients that underwent the separate best practice interventions if applicable
Time frame: Through study completion, on average up to 25 months
Registry outcomes
Best practice registrations measured through Patient Reported Outcome Measures
Time frame: Through study completion, on average up to 25 months
Registry outcomes
Best practice registrations measured through the Dutch Pancreatic Cancer Audit
Time frame: Through study completion, on average up to 25 months
Registry outcomes
Best practice registrations measured through the Netherlands Cancer Registry
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
VU Medical Center
Amsterdam, Netherlands
Amphia
Breda, Netherlands
Reinier de Graaf Gasthuis
Delft, Netherlands
Catharina
Eindhoven, Netherlands
Medisch Spectrum Twente
Enschede, Netherlands
University Medical Center Groningen
Groningen, Netherlands
Tjongerschans
Heerenveen, Netherlands
...and 7 more locations
Time frame: Through study completion, on average up to 25 months
Use of smartphone application
Time frame: Through study completion, on average up to 25 months